henk-jan guchelaar
henk-jan guchelaar
Leiden University Medical center
Verified email at lumc.nl - Homepage
Cited by
Cited by
Genetics of rheumatoid arthritis contributes to biology and drug discovery
Y Okada, D Wu, G Trynka, T Raj, C Terao, K Ikari, Y Kochi, K Ohmura, ...
Nature 506 (7488), 376-381, 2014
Pharmacogenetics: from bench to byte—an update of guidelines
JJ Swen, M Nijenhuis, A de Boer, L Grandia, AH Maitland‐van der Zee, ...
Clinical Pharmacology & Therapeutics 89 (5), 662-673, 2011
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
A Vermes, HJ Guchelaar, J Dankert
Journal of Antimicrobial Chemotherapy 46 (2), 171-179, 2000
The risk of cancer in users of statins
MR Graaf, AB Beiderbeck, ACG Egberts, DJ Richel, HJ Guchelaar
Journal of clinical oncology 22 (12), 2388-2394, 2004
Cardiotoxicity of cytotoxic drugs
KJM Schimmel, DJ Richel, RBA van den Brink, HJ Guchelaar
Cancer treatment reviews 30 (2), 181-191, 2004
Clinical pharmacokinetics of tyrosine kinase inhibitors
NP van Erp, H Gelderblom, HJ Guchelaar
Cancer treatment reviews 35 (8), 692-706, 2009
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis
JAM Wessels, TWJ Huizinga, HJ Guchelaar
Rheumatology 47 (3), 249-255, 2008
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
MR Graaf, DJ Richel, CJF van Noorden, HJ Guchelaar
Cancer treatment reviews 30 (7), 609-641, 2004
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single‐nucleotide polymorphisms in genes coding for folate pathway enzymes
JAM Wessels, JK de Vries‐Bouwstra, BT Heijmans, PE Slagboom, ...
Arthritis & Rheumatism 54 (4), 1087-1095, 2006
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent‐onset rheumatoid arthritis
JAM Wessels, SM van der Kooij, S le Cessie, W Kievit, P Barerra, ...
Arthritis & Rheumatism 56 (6), 1765-1775, 2007
Liposomal drug formulations in cancer therapy: 15 years along the road
M Slingerland, HJ Guchelaar, H Gelderblom
Drug discovery today 17 (3-4), 160-166, 2012
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
NP van Erp, K Eechoute, AA van der Veldt, JB Haanen, AK Reyners, ...
J Clin Oncol 27 (26), 4406-12, 2009
Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment
HJ Guchelaar, A Vermes, JH Meerwaldt
Supportive care in cancer 5 (4), 281-288, 1997
Pharmacogenetics: from bench to byte
JJ Swen, I Wilting, AL De Goede, L Grandia, H Mulder, DJ Touw, ...
Clinical Pharmacology & Therapeutics 83 (5), 781-787, 2008
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer
MJ Deenen, J Tol, AM Burylo, VD Doodeman, A De Boer, A Vincent, ...
Clinical Cancer Research 17 (10), 3455-3468, 2011
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
DM Kweekel, H Gelderblom, HJ Guchelaar
Cancer treatment reviews 31 (2), 90-105, 2005
Translating pharmacogenomics: challenges on the road to the clinic
JJ Swen, TW Huizinga, H Gelderblom, EGE De Vries, WJJ Assendelft, ...
PLoS Med 4 (8), e209, 2007
Making sense of big data in health research: towards an EU action plan
C Auffray, R Balling, I Barroso, L Bencze, M Benson, J Bergeron, ...
Genome medicine 8 (1), 1-13, 2016
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib
AAM van der Veldt, K Eechoute, H Gelderblom, J Gietema, HJ Guchelaar, ...
Clinical Cancer Research 17 (3), 620-629, 2011
Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer
VO Dezentjé, NJC van Blijderveen, H Gelderblom, H Putter, ...
Journal of Clinical Oncology 28 (14), 2423-2429, 2010
The system can't perform the operation now. Try again later.
Articles 1–20